Transcriptional signatures of human peripheral blood mononuclear cells can identify the risk of tuberculosis progression from latent infection among individuals with silicosis.
Transcriptional signatures of human peripheral blood mononuclear cells can identify the risk of tuberculosis progression from latent infection among individuals with silicosis.
复制标题
人外周血单核细胞的转录特征可以识别矽肺患者潜伏感染导致结核病进展的风险
DOI:
10.1080/22221751.2021.1915184
复制
发表时间:
2021-12
影响因子:
13.2
通讯作者:
Zhang WH
中科院分区:
文献类型:
--
作者:
Ruan QL;Yang QL;Gao YX;Wu J;Lin SR;Zhou JY;Shao LY;Wang S;Liu QQ;Gao Y;Jiang N;Zhang WH
ABSTRACT Host immune factor plays an important role in the progression of latent tuberculosis infection (LTBI) to active tuberculosis (TB) disease. However, whether global gene expression measured in blood biomarkers allows the identification of prospective signatures for TB risk remains unknown. Hence, we aimed to assess the ability of the transcriptome signatures in the human peripheral blood mononuclear cells (PBMCs) of LTBI subjects to differentiate future TB progressors from non-progressors. In a randomized clinical trial of TB preventive treatment of 513 participants with silicosis, we randomly collected PBMC samples from 50 LTBI subjects in the observational group, which was monitored for TB disease progression for 37 months. The prospective signatures of TB risk between the two participants who developed active TB (progressors) and four matched individuals who remained healthy (non-progressors) were compared using differential expression analysis, Gene Ontology analysis, Kyoto Encyclopedia of Genes and Genomes pathway analysis, and Weighted Gene Co-expression Network Analysis. The 20 TB-specific differentially expressed genes, which were significantly downregulated in TB progressors, were revealed to be associated with interferon-gamma response-related genes. Therefore, the PBMC transcriptome profiles analyzed in this study may help identify LTBI individuals who are at risk of progressing to active TB among silicosis patients and may provide new insights for targeted intervention to prevent disease progression. Clinical trial registration www.clinicaltrials.gov (NCT02430259)
登录
查看更多内容
影响因子:
16.6
作者:
Singhania A;Verma R;Graham CM;Lee J;Tran T;Richardson M;Lecine P;Leissner P;Berry MPR;Wilkinson RJ;Kaiser K;Rodrigue M;Woltmann G;Haldar P;O'Garra A
通讯作者:
O'Garra A
影响因子:
56.3
作者:
Rangaka, Molebogeng X.;Wilkinson, Katalin A.;Glynn, Judith R.;Ling, Daphne;Menzies, Dick;Mwansa-Kambafwile, Judith;Fielding, Katherine;Wilkinson, Robert J.;Pai, Madhukar
通讯作者:
Pai, Madhukar
影响因子:
64.8
作者:
通讯作者:
--
影响因子:
2.8
作者:
Stirling C;Andrews S;Croft T;Vickers J;Turner P;Robinson A
通讯作者:
Robinson A
影响因子:
4.4
作者:
Denisenko, Elena;Guler, Reto;Schmeier, Sebastian
通讯作者:
Schmeier, Sebastian